Literature DB >> 7557613

Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma.

P J Eifel1, T W Burke, M Morris, T L Smith.   

Abstract

Between 1960 and 1989 1538 patients were treated with initial radiation therapy for FIGO Stage IB squamous cell carcinoma (SCC) of the cervix and 229 patients were treated for Stage IB adenocarcinoma (AC). The overall 5-year survival rates for patients with SCC and AC were 81 and 72%, respectively (P < 0.01). Patients with AC more often had a maximum cervical diameter < 4 cm than those with SCC (53% versus 47%). For 903 patients with tumors > or = 4 cm, 73% of those with SCC survived > or = 5 years compared with only 59% of those with AC (P < 0.01). Although there was no significant difference in the rate of pelvic disease recurrence for patients with AC or SCC tumors > or = 4 cm (17% versus 13%, P = 0.16), the rate of distant metastases was greater for patients with AC (37% vs 21%, P < 0.01). For patients with tumors > or = 4 cm, prognosis was strongly correlated with tumor size (P < 0.01) and lymphangiogram findings (P < 0.01) but not with age (P = 0.58) or tumor morphology (exophytic versus endocervical) (P = 0.33); a trend toward better survival in 165 patients who underwent adjuvant hysterectomy (78% versus 71%) was not significant (P = 0.09). Multivariate analysis confirmed a highly significant independent association between histology and survival; patients with tumors > or = 4 cm in diameter that were AC had an estimated risk of death 1.9 times that of patients with SCC (P < 0.01). These results provide strong evidence that patients with AC of the cervix have a poorer prognosis than those with SCC of similar stage and tumor diameter, reflecting primarily a higher rate of distant metastases in patients with AC.

Entities:  

Mesh:

Year:  1995        PMID: 7557613     DOI: 10.1006/gyno.1995.1265

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  50 in total

1.  Response of adenocarcinoma of the uterine cervix to chemoradiotherapy.

Authors:  Orit Kaidar-Person; Sawsan Yosefia; Roxolyana Abdah-Bortnyak
Journal:  Oncol Lett       Date:  2015-04-08       Impact factor: 2.967

2.  Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.

Authors:  Muneaki Shimada; Shoji Nagao; Keiichi Fujiwara; Nobuhiro Takeshima; Ken Takizawa; Tadahiro Shoji; Toru Sugiyama; Satoshi Yamaguchi; Ryuichiro Nishimura; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2016-07-05       Impact factor: 3.402

3.  Apoptosis Phenomena in Squamous Cell Carcinomas and Adenocarcinomas of the Uterine Cervix.

Authors:  Mariana Gamba De Paula Eduardo; Adriana Bittencourt Campaner; Maria Antonieta Longo Galvão Silva
Journal:  Pathol Oncol Res       Date:  2015-02-15       Impact factor: 3.201

4.  A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.

Authors:  Xiuzhen Xie; Kun Song; Baoxia Cui; Jie Jiang; Xingsheng Yang; Beihua Kong
Journal:  Int J Clin Oncol       Date:  2018-01-03       Impact factor: 3.402

5.  Adjuvant radiochemotherapy in patients with locally advanced high-risk cervical cancer.

Authors:  F Heinzelmann; G Henke; M von Grafenstein; N Weidner; F Paulsen; A Staebler; S Brucker; M Bamberg; M Weinmann
Journal:  Strahlenther Onkol       Date:  2012-05-23       Impact factor: 3.621

6.  Analysis of HGF, MACC1, C-met and apoptosis-related genes in cervical carcinoma mice.

Authors:  Xiao-Ping Chen; Xin-Ping Ren; Jian-Yun Lan; You-Guo Chen; Zong-Ji Shen
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

7.  Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer.

Authors:  Nina A Mayr; William T C Yuh; David Jajoura; Jian Z Wang; Simon S Lo; Joseph F Montebello; Kyle Porter; Dongqing Zhang; D Scott McMeekin; John M Buatti
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

8.  Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix.

Authors:  J-Y Park; D-Y Kim; J-H Kim; Y-M Kim; Y-T Kim; J-H Nam
Journal:  Br J Cancer       Date:  2010-06-08       Impact factor: 7.640

9.  Outcomes of planned delivery delay in pregnant patients with invasive gynecologic cancer.

Authors:  Shin-ichi Ishioka; Yoshiaki Ezaka; Toshiaki Endo; Kunihiko Nagasawa; Ayumi Shimizu; Akiyasu Sato; Marie Inoue; Tsuyoshi Saito
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

10.  Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix.

Authors:  T Kasamatsu; T Onda; M Sawada; T Kato; S Ikeda; Y Sasajima; H Tsuda
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.